The Company
Dexcom Corporation (NASDAQ: DXCM) ist ein Pionier und weltweit führend im Bereich der kontinuierlichen Glukoseüberwachung (CGM). Dexcom begann als kleines Unternehmen mit einem großen Traum: Die Art und Weise, wie Diabetes behandelt wird, für immer zu verändern. Informationen und Erkenntnisse zugänglich zu machen, die zu besseren gesundheitlichen Ergebnissen führen. Heute, 25 Jahre später, haben wir eine ganze Branche geprägt – und wir stehen erst am Anfang. Wir erweitern unsere Vision über Diabetes hinaus, um Menschen zu befähigen, ihre Gesundheit selbst in die Hand zu nehmen. Das bedeutet: personalisierte, umsetzbare Erkenntnisse, die darauf abzielen, wichtige gesundheitliche Herausforderungen zu lösen. Unser Ziel bleibt: Die menschliche Gesundheit zu verbessern.
Angetrieben werden wir von Tausenden ehrgeiziger, leidenschaftlicher Menschen weltweit, die wie Kämpfer darum ringen, das Vertrauen unserer Kundinnen und Kunden zu gewinnen – durch Zuhören, Integrität, große Visionen und Verlässlichkeit. Wir haben bereits Millionen Leben verändert – und sind bereit, Millionen weitere zu verändern.
Unsere Zukunftsvision ist es, ein führendes Unternehmen im Bereich der Gesundheitstechnologie für Verbraucher zu werden, während wir weiterhin Lösungen für ernsthafte Gesundheitsprobleme entwickeln. Wir werden dieses Ziel erreichen, indem wir kontinuierlich einzigartige Erfahrungen mit Biosensor-Technologie neu erfinden. Auch wenn wir weit von unseren Anfängen als kleines Unternehmen entfernt sind – unsere Träume sind größer denn je. Die Chance, die Gesundheit weltweit zu verbessern, liegt vor uns.
Lerne das Team kennen:
Du arbeitest als Führungskraft im Sales Team der Dexcom Deutschland GmbH und bist für die Erreichung der Umsatz- und Neupatientenziele für deine Region verantwortlich. Durch empathisches In-Field Coaching und Motivation deines Teams schaffst du es, die nötige Qualität und Quantität an Kundeninteraktionen zu bewerkstelligen um den Einsatz des Dexcom G7 und Dexcom FLEX weiter voranzutreiben. Dabei bist du mindestens drei Tage in der Woche mit deinem Team bei Kunden präsent und übernimmst die Aufgabe der regionalen KOL Betreuung. „Transform & Perform“ bedeutet für dich, sich den aktuellen Marktherausforderungen zu stellen, diese zu meisten und dabei den strategischen Weitblick für die Herausforderungen des Verkaufs in der Zukunft zu haben. Dexcom ist Pionier in der Entwicklung von CGM Systemen, werde Teil unseres Teams und fordere den Status Quo heraus!
Wo du ins Spiel kommst:
Was dich erfolgreich macht:
Was Du erhälst:
Erfahrung und Ausbildung:
Reisen:
Remote-Arbeitsplatz: Dein Arbeitsort wird ein Homeoffice sein; Du musst nicht in Pendelentfernung zu Deinem Dexcom-Standort wohnen (in der Regel innerhalb einer Stunde Fahrtzeit). Wenn Du in Pendelentfernung zu einem Dexcom-Standort wohnst (in der Regel innerhalb einer Stunde Fahrtzeit), kann eine hybride Arbeitsumgebung verfügbar sein. Erkundige dich nach unserer Flex-/Hybrid-Option.
An alle Personalvermittlungs- und Rekrutierungsagenturen: Unsere Karriereseite ist nur für Personen bestimmt, die eine Stelle bei Dexcom suchen. Nur autorisierte Personalvermittlungs- und Rekrutierungsagenturen dürfen diese Seite nutzen oder Profile, Bewerbungen oder Lebensläufe zu bestimmten Stellenangeboten einreichen. Dexcom akzeptiert keine unaufgeforderten Lebensläufe oder Bewerbungen von Agenturen. Bitte leiten Sie keine Lebensläufe an das Talent Acquisition Team, an Dexcom-Mitarbeiter:innen oder an eine andere Stelle im Unternehmen weiter. Dexcom ist nicht für Gebühren im Zusammenhang mit unaufgeforderten Lebensläufen/Bewerbungen verantwortlich.
Hinweis zur Nutzungvon künstlicher Intelligenzbei der Personalauswahl: Wir nutzen möglicherweise KI-gestützte Tools, um unseren Einstellungsprozess effizienter, einheitlicher und für Bewerber weltweit zugänglicher zu gestalten. Sämtliche Einstellungsentscheidungen werden von Menschen getroffen.
Bei Dexcom legen wir großen Wert auf einen fairen, inklusiven und geschlechtsneutralen Einstellungsprozess und Bewerber aller Geschlechter und Geschlechtsidentitäten dazu ermutigen, sich zu bewerben.
Sollte eine Formulierung in dieser Beschreibung dennoch einmal geschlechtsspezifisch oder ausgrenzend wirken, ist dies nicht beabsichtigt.
Sollte eine angemessene Vorkehrung zur Unterstützung bei einer Behinderung erforderlich sein, sollten entsprechende Anfragen an die Talent Acquisition von Dexcom gesendet werden [email protected].
#DACH
Dexcom develops continuous glucose monitoring systems to help people manage diabetes by giving real-time glucose readings. Its main product, the Dexcom G6 CGM System, uses a wearable sensor and transmitter to send data to a display device or smartphone without requiring finger-prick calibrations. The company also offers Dexcom CLARITY analytics software and subscription services to manage and share glucose data with clinicians and caregivers. Dexcom differentiates itself with a complete CGM ecosystem that combines real-time data, a factory-calibrated sensor, and integrated analytics and data-sharing features to support patients, families, and healthcare providers, with a goal of improving quality of life for people with diabetes through accurate, easy-to-use monitoring and actionable insights.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1999
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Piper Sandler sets USD 160.00 target for iRhythm stock. Published on 10/20/2026 at 21:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Piper Sandler sets a USD 160.00 target on October 16, 2026. iRhythm stock costs EUR 101.50 on October 20, 2026, up 4.25 percent on Nasdaq. Analyst coverage and trading. * Piper Sandler began coverage with a USD 160.00 target on October 16, 2026. * Second-quarter revenue reached USD 224.17 million, up 20.1 percent year over year. * iRhythm stock costs EUR 101.50 at Lang & Schwarz on October 20, 2026 at 9:45 p.m. CEST, with Nasdaq trading up 4.25 percent. * Third-quarter results are scheduled for November 5, 2026. iRhythm Technologies (ISIN US4500561067) drew a USD 160.00 price target when MarketScreener reported Piper Sandler's new Overweight rating on October 16, 2026. The target stands 40.04 percent above the Nasdaq price of USD 114.25 at 3:51 p.m. ET on October 20, 2026. After hours, the stock was trading at EUR 101.50 at Lang & Schwarz on October 20, 2026 at 9:45 p.m. CEST, while Nasdaq trading was up 4.25 percent. Revenue reached USD 224.17 million. The latest reported quarter gives the analyst view an operating anchor. According to iRhythm, revenue in the second quarter of 2026 reached USD 224.17 million, up 20.10 percent from USD 186.69 million in the second quarter of 2025. Gross margin rose to 72.80 percent from 71.20 percent, while adjusted EBITDA increased to USD 43.30 million from USD 15.70 million. The quarter also marked a sharp improvement in adjusted profitability. Adjusted net income was USD 19.32 million in the second quarter of 2026, compared with an adjusted net loss of USD 10.22 million in the same quarter of 2025. Stock remains near its yearly low. The Nasdaq quote places iRhythm at USD 114.25, versus a 52-week range of USD 100.70 to USD 212.00 as of October 20, 2026. The price therefore stood 43.16 percent below the yearly high and 13.45 percent above the yearly low. The market capitalization was USD 3.8 billion, with 379,512 shares traded by 3:51 p.m. ET. Valuation and next reporting date. For comparison, DexCom traded at USD 85.71 on October 20, 2026, down 0.31 percent, with a price-to-earnings ratio of 33.86 and market capitalization of USD 32.3 billion. Insulet traded at USD 142.87, up 0.64 percent, with a price-to-earnings ratio of 26.70 and market capitalization of USD 9.9 billion. MarketScreener lists November 5, 2026 as the date for iRhythm's third-quarter 2026 financial results. The USD 160.00 target from October 16, 2026 remains the clearest dated analyst reference in the current trading picture. Price and analyst target. The euro quote and the Nasdaq price describe separate venues, but both place the stock well below Piper Sandler's USD 160.00 target. The next results date will provide the next formal test of the company's USD 880 million to USD 890 million full-year 2026 revenue outlook. The further course of trading is shown by the continuously updated real-time quote of iRhythm stock. iRhythm Technologies market data. * Company: iRhythm Technologies, Inc. * ISIN: US4500561067 * Ticker: IRTC * Primary exchange: Nasdaq * Price Lang & Schwarz as of October 20, 2026, 9:45 p.m. CEST: EUR 101.50 * Change on Nasdaq: plus 4.25 percent as of October 20, 2026 * Market capitalization: USD 3.8 billion as of October 20, 2026 * 52-week range: USD 100.70-212.00 as of October 20, 2026 * Sector / Industry: Healthcare / Medical Devices * Next earnings date: November 5, 2026 Sponsored Ad iRhythm stock: new analysis - 22 October. Fresh iRhythm information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US4500561067 | IRMD | boerse | 70378236 | bgmi
Ransomware Group Redact hits: dexcom. HookPhish team Target organization DexCom dexcom.com Healthcare Summary. In the latest cybersecurity news, DexCom - an organization based in US - has fallen victim to a ransomware attack conducted by the group Redact. This data breach, discovered on Oct 10, 2026, 16:53 UTC, underscores the increasing need for proactive cybersecurity defenses as HookPhish continue through 2026. Incident report. | Target Organization | DexCom | | Threat Group | Redact | | Summary | Sector: Medical Equipment | Revenue: $4.97B USD | | Date of Breach | Oct 10, 2026, 16:53 UTC | | Discovery Date | Oct 10, 2026, 16:53 UTC | | Region | US | | Target Domain | dexcom.com | | Business Sector | Healthcare | How to reduce your ransomware risk. Most ransomware intrusions start with a stolen password or a phishing email. A few proactive steps sharply cut your exposure: * security awareness training - close the gap attackers exploit. * dark web monitoring - close the gap attackers exploit. Disclaimer. HookPhish does not engage in the exfiltration, downloading, taking, hosting, viewing, reposting, or disclosure of any stolen information. All breach data reported here is sourced from publicly available threat intelligence feeds for awareness purposes only.
DexCom Data Breach investigation. Migliaccio & Rathod LLP is investigating the possible DexCom Data Breach, impacting an unknown number of individuals and their personal information. What happened? On October 5, 2026, dark web monitoring sites reported that DexCom had been named as a victim of a data breach. Little information is available at this time regarding the nature of the breach or the data that may have been involved, but the affected information is believed to include sensitive and personal data. DexCom Data Breach. All of the information possibly stolen is likely valuable and dangerous to affected individuals. As seen in other cyberattacks, victims of data theft have reported identity theft attempts, fraudulent charges on bank or credit card accounts, unauthorized credit applications, misuse of medical or government services, exposure of information on the dark web, and a significant increase in spam calls, text messages, and emails. Are you concerned that you might be affected by the DexCom data breach? If you have concerns that your personal information may have been affected by this incident, and/or you have experienced suspicious activity recently, Migliaccio & Rathod LLP would like to hear from you. Please complete the contact form on this page, email Migliaccio & Rathod LLP at [email protected], or call Migliaccio & Rathod LLP at (202) 470-3520. The following will ask for your contact information so that Migliaccio & Rathod LLP may reach you to talk about potential claims. This information is for its records only and will not be shared. By continuing, you consent to the collection of this information for these limited purposes. Did you receive a notification that you were affected by the data breach? Would you like to join its newsletter to receive notifications about other investigations Migliaccio & Rathod LLP is looking into, as well as updates on ongoing cases? By submitting this form, you consent to receive marketing, updates, and informative SMS messages from Migliaccio & Rathod LLP at the email and/or phone number provided. Message & data rates may apply. Message frequency varies. Unsubscribe at any time by replying STOP or Reply HELP for help. Privacy Policy The lawyers at Migliaccio & Rathod LLP have years of experience in class action litigation against large corporations, including in cases involving data breaches such as this. More information about its current cases and investigations is available on its blog. To learn more about data breach litigation, you can listen here to the firm partners' explanation. Data Breach FAQ. I received a notice that my information may have been involved in a data breach. What should I do? If you receive a notification, take it seriously and read it carefully. It should identify what specific information may have been affected. Even if you believe your risk is minimal, it is best to take proactive steps to protect yourself. What immediate actions should I take? * Monitor your financial accounts - Regularly review your bank, credit card, and online accounts for unauthorized activity. * Change your passwords - Update passwords for any accounts that may be connected to the breach and avoid reusing passwords across platforms. * Enable two-factor authentication (2FA) - Use 2FA where available to add an additional layer of security. * Place a fraud alert or credit freeze - Contact Equifax, Experian, or TransUnion to help prevent unauthorized accounts from being opened in your name. What is credit monitoring, and how should I use it? Credit monitoring services watch for changes to your credit report and can alert you to potential fraudulent activity. If offered by a company at no cost, enrollment is strongly recommended. How long do I need to stay vigilant? The effects of a data breach can surface months or even years later. Remain alert for signs of identity theft for at least 12 to 24 months. Who can I contact if I need help? You can use the contact details provided in the breach notification. You can also report identity theft at www.identitytheft.gov for recovery resources. Migliaccio & Rathod LLP is here to be a resource to you. Fill out the contact form above to get in touch with Migliaccio & Rathod LLP.
Dexcom faces lawsuit alleging device failures endangered children. New lawsuits have been filed alleging Dexcom G7 glucose monitors malfunctioned, causing life-threatening emergencies in children, bringing total litigation to 11 cases. Claire Wallace, Senior Writer, Informa Markets - Engineering October 2, 2026 Morgan & Morgan has filed two additional lawsuits against Dexcom, Inc., alleging the company's G7 continuous glucose monitors malfunctioned and caused severe medical emergencies in children, bringing the firm's total litigation against the medical device manufacturer to 11 cases. The latest lawsuits involve a 7-year-old California girl and a 10-year-old Tennessee girl who were both hospitalized after their Dexcom G7 devices allegedly failed to accurately report blood glucose levels. The California lawsuit centers on a November 2025 incident in which a 7-year-old girl was hospitalized with profound diabetic ketoacidosis, a life-threatening complication that occurs when the body lacks sufficient insulin. According to the complaint, her Dexcom G7 malfunctioned and significantly misreported her glucose levels, preventing her family from recognizing that her blood sugar had reached dangerous levels. The Tennessee lawsuit involves a 10-year-old girl who was rushed to the hospital in August 2025 after her Dexcom G7 allegedly failed to alert her family that her blood sugar had dropped to dangerously low levels. By the time she arrived at the hospital, the lawsuit alleges her condition had deteriorated so severely that she experienced convulsive seizures requiring physical restraint by medical professionals. "Dexcom marketed this device as a safe and accurate replacement for finger sticks," said Morgan & Morgan founder John Morgan in a statement. "In doing so, they garnered the trust of parents of diabetic children who have come to depend on it to keep their children safe, but some of the devices allegedly did not work properly." Morgan & Morgan attorneys Shannon Pennock and Jack Rutherford emphasized the firm's commitment to accountability. "These lawsuits are about accountability," they said. "We want to ensure no one else is harmed by a device they depend on to survive." The firm has now filed 11 lawsuits against Dexcom involving both the G7 and earlier-generation G6 glucose monitors on behalf of plaintiffs across California, Florida, New Jersey, Tennessee, Kentucky, and Louisiana. Three cases involve minors, while four allege that Dexcom users died from medical events that plaintiffs contend could have been prevented had the devices functioned properly. The Dexcom G7 has also been subject to multiple recalls. The complaints were filed in the Superior Court of the State of California - County of San Diego, where Dexcom's global headquarters are located. The company is currently working on its next iteration, the Dexcom G8, despite a plethora of ongoing G7 concerns. Senior Writer, Informa Markets - Engineering Claire Wallace is a senior staff writer at Medical Device + Diagnostics Industry (MD+DI), where she covers key developments in the healthcare and medical device industry. With nearly a decade of journalism experience, she brings a deep understanding of the healthcare industry and a proven ability to connect with physicians, medtech leaders, and policy experts on the issues shaping care delivery today. She is committed to delivering nuanced coverage that helps industry professionals anticipate trends, understand regulatory shifts, and identify opportunities in an increasingly complex healthcare ecosystem. Before joining MD+DI, Claire spent three years at Becker's Healthcare as a writer and assistant editor, leading coverage on developments across orthopedics, outpatient care, cardiology, and gastroenterology that bridged perspectives from clinicians and healthcare executives. Her reporting background also includes lifestyle, political, and clean energy news, with bylines in various national and digital publications. Claire earned her bachelor's degree in Communications and Media & Screen Studies from Northeastern University, where she also minored in Political Science and Journalism. She holds a master's degree in Media Advocacy and is currently based in Chicago. Want more MD+DI in your search results?
Heidi rolls out AI agents and more briefs. Also, Dexcom and Health2Sync are extending their integrated CGM offering to Australia and Singapore. By Adam Ang | October 2, 2026 | 12:59 AM Heidi introduces AI agents Heidi has unveiled the latest version of its AI platform with AI agents that perform administrative tasks around patient visits. The upgraded platform features new AI agents that can plan and execute tasks such as pre-charting, referral communications, panel reviews and follow-up work across EHRs, calendars, inboxes and patient portals. Heidi maintained that clinicians retain approval and control over decision-making. Heidi II rollout began in late September in English and French outside the United Kingdom and European Union. Dexcom, Health2Sync expand APAC integration CGM maker Dexcom and Taipei-based Health2Sync are expanding their diabetes technology partnership to Australia and Singapore, extending an existing collaboration in Japan. The collaboration offers Health2Sync's digital platform that can be integrated with Dexcom's continuous glucose monitoring (CGM) data. The integrated offering will go live in the "next few months," Dexcom said in a LinkedIn post. Qld AI launchpad bags fed grant Queensland University of Technology (QUT) researchers have received an A$1.49 million (about $1 million) federal government grant to develop and evaluate AI launchpads intended to help health services implement and sustain AI in routine care. According to a media release, the project will work with clinicians, consumers, digital health researchers and industry to build local systems and workforce capabilities for procuring proprietary AI, adapting tools from other health services and developing and evaluating AI within health service environments. Partners include health services: Metro South, Children's Health Queensland, Sunshine Coast, West Moreton, Mackay, Queensland Health, as well as Microsoft Australia and the Australian Institute of Digital Health.